levoleucovorin and Teratoma

levoleucovorin has been researched along with Teratoma* in 6 studies

Reviews

1 review(s) available for levoleucovorin and Teratoma

ArticleYear
The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: a case report and review.
    Cancer, 1997, Sep-01, Volume: 80, Issue:5

    The growing teratoma syndrome is a recognized complication of metastatic nonseminomatous germ cell tumors of the testis and is managed surgically. It may also occur in intracranial nongerminomatous germ cell tumors.. The authors performed an English language computer search using the EMBASE data base (from January 1980 to December 1996) for pineal tumors, read all abstracts, and then selected all articles pertaining to germ cell tumors at this site.. The case history of a 19-year-old male who presented with a pineal nongerminomatous germ cell tumor, which was treated with chemotherapy, is reported. Despite normalization of raised tumor marker levels, the pineal mass enlarged during chemotherapy. This was excised and proved to be a mature teratoma. A review of the literature regarding this complication of intracranial germ cell tumors is also presented.. The authors believe this to be the first reported case of growing teratoma syndrome in the pineal gland of an adult patient, two previously reported cases occurred in children. The authors conclude that the pineal gland is an unusual but important site in which to recognize the growing teratoma syndrome.

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Diagnosis, Differential; Endodermal Sinus Tumor; Etoposide; Humans; Leucovorin; Male; Methotrexate; Neoplasms, Germ Cell and Embryonal; Neoplasms, Second Primary; Pineal Gland; Syndrome; Teratoma; Vincristine

1997

Other Studies

5 other study(ies) available for levoleucovorin and Teratoma

ArticleYear
Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report.
    Archives of Iranian medicine, 2009, Volume: 12, Issue:2

    Malignant transformation in a mature cystic teratoma of the ovary is rare. The most common malignancy is squamous cell carcinoma, which consists of about 75% of malignant transformations. In the present report, we describe a case of advanced-stage squamous cell carcinoma arising in a mature cystic teratoma. A postmenopausal 63-year-old woman with squamous cell carcinoma arising in a mature cystic teratoma is presented. The initial investigation by ultrasound showed a left adnexal mass with mixed echo pattern, which arose the suspension of malignancy. She underwent a laparotomy and left oophorectomy. Histopatholog was compatible with squamous cell carcinoma arising in a mature cystic teratoma. After a few episodes of intestinal obstruction and colostomy, she underwent partial resection of the ileum and sigmoid colon four months after the initial oophorectomy. Histopathologic study showed metastatic poorly-differentiated squamous cell carcinoma. Subsequently, she underwent two courses of combination chemotherapy with cisplatin, leucovorin, and 5-fluorouracil with no response. She died from progression of the disease nine months after the initial operation.

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Colostomy; Fatal Outcome; Female; Fluorouracil; Humans; Ileal Neoplasms; Intestinal Obstruction; Leucovorin; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Ovariectomy; Sigmoid Neoplasms; Teratoma; Ultrasonography; Vitamin B Complex

2009
Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells.
    Cancer research, 1986, Volume: 46, Issue:8

    Methotrexate (MTX) conjugates of a monoclonal antibody, anti-SSEA-1, containing an average of 45 mol MTX/mol of immunoglobulin M, were prepared by a carbodiimide coupling reaction. Binding experiments indicate that conjugation does not decrease the affinity of the antibody for its antigen. The conjugate strongly inhibits the growth of SSEA-1-bearing F-9 teratocarcinoma cells, with 50% inhibitory dose of 4.5 nM MTX, which makes it more active than free MTX (50% inhibitory dose of 15 nM). The drug-free antibody is not cytotoxic to F-9 cells at the concentrations used. The high efficacy of the conjugated drug may be due in part to the fact that anti-SSEA-1 antibody is an immunoglobulin M. MTX conjugated to nonspecific immunoglobulin M has little inhibitory effect (50% inhibitory dose of 150 nM). When acting on SSEA-1 negative cells, the two conjugates have only a small but identical effect. Thiamine pyrophosphate, an inhibitor of MTX transport, can prevent the cytotoxicity of the free MTX but not that of the anti-SSEA-1 conjugate. Leupeptin, an inhibitor of lysosomal protease, can partially protect F-9 cells against the antibody conjugate but not against free MTX. These results indicate that the MTX antibody conjugate binds specifically to F-9 cells, and is internalized and intracellularly degraded to release a small molecular active drug. Pretreatments of F-9 cells for 1 h with unlabeled antibody inhibits the subsequent uptake of identical concentration of labeled conjugate. The rate of internalization, however, regains almost normal values within 4 h, indicating a rapid reappearance of free antigenic sites at the cell surface.

    Topics: Animals; Antibodies, Monoclonal; Glycolipids; Immunoglobulin G; Leucovorin; Leupeptins; Lewis X Antigen; Lysosomes; Methotrexate; Mice; Mice, Inbred BALB C; Teratoma; Thiamine Pyrophosphate; Tritium

1986
Methodichlorophen as anti-tumor drug.
    British medical journal, 1975, Apr-05, Volume: 2, Issue:5961

    Methodichlorophen was given to 26 patients with terminal malignant disease. Eight patients received adequate doses, and five of them showed objective evidence of tumour regression while three failed to respond. Those who responded included four out of five patients with lung cancer (three with squamous-cell carcinoma and one with oat-cell carcinoma) and a patient with hypernephroma. Two patients with testicular teratomas and one with acute myeloid leukemia failed to respond. The drug may be given safely by mouth to outpatients if certain precautions are taken.

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Marrow Diseases; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chlorobenzenes; Drug Therapy, Combination; Erythema; Headache; Humans; Kidney Neoplasms; Leucovorin; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pyrimethamine; Pyrimidines; Teratoma; Testicular Neoplasms

1975
Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.
    Cancer research, 1974, Volume: 34, Issue:12

    Topics: Adolescent; Age Factors; Aspartate Aminotransferases; Child; Child, Preschool; Female; Half-Life; Hematopoiesis; Humans; Kidney; Leucovorin; Liposarcoma; Methotrexate; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma, Ewing; Teratoma

1974
Prolonged intravenous methotrexate therapy in the treatment of acute leukemia and solid tumors.
    Cancer research, 1970, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Child, Preschool; Choriocarcinoma; Chorionic Gonadotropin; Female; Humans; Infusions, Parenteral; Injections, Intravenous; Leucovorin; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Methotrexate; Middle Aged; Pregnancy; Teratoma; Testicular Neoplasms

1970